PMID- 23233526
OWN - NLM
STAT- MEDLINE
DCOM- 20130605
LR  - 20181202
IS  - 1937-9145 (Electronic)
IS  - 1945-0877 (Linking)
VI  - 5
IP  - 254
DP  - 2012 Dec 11
TI  - Comment on "epidermal growth factor receptor is essential for toll-like receptor 
      3 signaling".
PG  - lc5
LID - 10.1126/scisignal.2003734 [doi]
AB  - Epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) 
      play important roles in tumor growth, which has stimulated efforts toward the 
      design of targeted cancer therapeutics that inhibit their function. A growing 
      body of literature indicates that EGFR and mTOR are also essential to support a 
      functional innate immune response. Hence, although combination therapies that 
      block both EGFR and mTOR may have improved activity against tumors, they may also 
      place patients at risk of fulminant infections. We discuss data supporting this 
      hypothesis.
FAU - Burtness, Barbara
AU  - Burtness B
AD  - Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, 
      USA.
FAU - Marur, Shanthi
AU  - Marur S
FAU - Bauman, Julie E
AU  - Bauman JE
FAU - Golemis, Erica A
AU  - Golemis EA
FAU - Mehra, Ranee
AU  - Mehra R
FAU - Cohen, Steven J
AU  - Cohen SJ
LA  - eng
PT  - Journal Article
DEP - 20121211
PL  - United States
TA  - Sci Signal
JT  - Science signaling
JID - 101465400
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Toll-Like Receptor 3)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - PQX0D8J21J (Cetuximab)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/adverse effects/pharmacology
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects
MH  - Cetuximab
MH  - ErbB Receptors/antagonists & inhibitors/*metabolism
MH  - Everolimus
MH  - Humans
MH  - Immunity, Innate/genetics/*physiology
MH  - Neoplasms/*drug therapy
MH  - Signal Transduction/genetics/*physiology
MH  - Sirolimus/adverse effects/analogs & derivatives/pharmacology
MH  - Toll-Like Receptor 3/antagonists & inhibitors/genetics/*metabolism
EDAT- 2012/12/13 06:00
MHDA- 2013/06/06 06:00
CRDT- 2012/12/13 06:00
PHST- 2012/12/13 06:00 [entrez]
PHST- 2012/12/13 06:00 [pubmed]
PHST- 2013/06/06 06:00 [medline]
AID - scisignal.2003734 [pii]
AID - 10.1126/scisignal.2003734 [doi]
PST - epublish
SO  - Sci Signal. 2012 Dec 11;5(254):lc5. doi: 10.1126/scisignal.2003734.